生命科学资讯

Aurora sets out to capitalize on FDA’s new framework for bespoke drug therapies

Aktis raises $318M in 2026’s first biotech IPO

Alveus launches with $160M to advance MariTide-like obesity drug

Parabilis, chasing ‘undruggable’ targets, nabs $305M amid VC funding blitz

Diagonal banks another $125M for ‘clustering’ antibody drugs

EpiBiologics raises $107M for its protein-degrading cancer drug

Lilly snaps up Ventyx for $1.2B in pursuit of oral immune drugs

GSK, Ionis claim study success for RNA-based hepatitis B drug

Arrowhead showcases early obesity data; Instil bails on PD-1/VEGF drug

5 FDA decisions to watch in the first quarter of 2026

Alumis soars as TYK2 drug hits mark in psoriasis trials

Amgen buys protein-degrading startup Dark Blue for up to $840M

CDC, following Trump’s orders, weakens US stance on childhood vaccinations

Surfing the AI wave: How pharma can harness agents in ERP

Moderna, searching for a rebound, to seek approval of mRNA flu shot

Zenas shares crash after top drug misses expectations in immune disease study

Novo launches Wegovy pill; Argenx to swap CEOs

10 clinical trials to watch in the first half of 2026

Strategic diagnostic testing partnerships are accelerating clinical research

Novo Nordisk’s weight loss pill approved by FDA